Information concerning the distribution of various subdomains of the amyloid precursor protein (APP) in brain may illuminate aspects of the normal metabolism of this membrane-associated protein, as well as putative abnormal processing that may occur in Alzheimer disease (AD). We prepared affinity-purified antibody, P2, against an extracytoplasmic APP site and applied it, along with monoclonal antibodies to the j3-peptide, or A4 region, in conjunction with selective cytochemical staining methods, to control and AD tissues. The following was noted: (i) in contrast to A4 epitopes, which are easily demonstrable primarily in extracellular senile plaques of AD patients, the extracytoplasmic P2 antigen was found in association with neurons, glia, and blood vessels in both normal and AD prefrontal cortex; (i) a subset of senile plaques contained both A4 and P2 antigens; (iU) in some instances, P2 antigen occurred as an extracellular deposit in the absence of A4; (iv) the P2 antigen, but not A4, was also associated with corpora amylacea. In addition to identifying the unique cellular distribution of the APP extracytoplasmic antigen, the results support the view that a segment of this domain undergoes processing and deposition at extracellular sites, including a subset of senile plaques.
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The structure of Alzheimer amyloid precursor protein (APP) cDNA has been determined (1) (2) (3) (4) (5) and shown to correspond to a protein of 695 amino acids that has features in common with glycosylated cell-surface receptors (1) . Of the APP domains, the A4 (or P-peptide) region consisting of -42 amino acids appears to extend from the extracytoplasmic domain to the transmembrane site (1) . Immunologic and biochemical data have firmly established that in the Alzheimer disease (AD) brain the A4 polypeptide is a major component of cerebrovascular and senile plaque amyloid (6) (7) (8) (9) (10) (11) . However, no detailed information has been available concerning the cellular or extracellular localization of the extracytoplasmic domain (ECD) of the APP and its distribution with regard to A4 and senile plaques.
The present report addresses the issue oflocalization ofthe ECD by means of an affinity-purified antibody, P2, raised to a unique peptide within the extracytoplasmic region of the APP. Both control and AD brains were stained with P2, anti-A4 monoclonal antibodies (mAbs) (10) , and anti-glial fibrillary acidic protein, in addition to selective cytochemical counterstains. We report here that an extracytoplasmic APP domain has unique features in both control and AD brains that distinguish it from A4. We report, further, that certain senile plaques of the AD brain contain the extracytoplasmic P2 antigen in addition to the A4 domain and that the P2 antigen alone can accumulate extracellularly.
A portion of these data were reported previously in preliminary form (12 
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. and dialyzed against 100 mM sodium phosphate (pH 7.4). The reactivity of antisera derived from immunizations with P2 alone or P2 conjugated to edestin gave the same immunocytochemical results. Therefore, sera were pooled and the combined antibodies are referred to as P2 antisera. Typically, 6 ml of serum led to the recovery of 1 ml of affinity-purified antibodies. This volume was used for dilution studies to assess the potency prior to using P2 for immunocytochemistry, as indicated in Results. Diluted antisera were assessed by the nitrocellulose immunoblot method, as detailed previously (10) .
Tissue Staining. Formalin-fixed tissue was cryopreserved with 30% sucrose and cut on a cryostat at 40 g&m. Tissue was processed with the avidin-biotin-horseradish peroxidase complex (Vector) that was visualized with diaminobenzidine (DAB) and H202, as described elsewhere (13) . For double immunostaining, either rhodamine-or fluorescein-conjugated goat anti-IgGs (Cappel) were used (14) . To increase the sensitivity of the reaction, a three-step procedure was used. Incubation with the primary antibody overnight at room temperature was followed by a 2-hr incubation with the appropriate biotinylated anti-IgG (Jackson Immunologicals) diluted 1:100 in Tris-buffered saline (TBS) plus 0.5% Triton X-100 (TBST) and 2% bovine serum albumin. This was followed by a 2-hr incubation with either Texas Red or fluorescein, each of which was conjugated to streptavidin (Jackson Immunologicals) diluted 1:100 in the same buffer. Antiserum to glial fibrillary acidic protein (GFAP) was purchased from Dako and has been described (14) . Antibodies to the A4 region of the APP were characterized in detail elsewhere (10 In contrast to anti-A4 mAbs (10), P2 stained normal control prefrontal cortex and reacted with both neuronal and apparent nonneuronal elements (Fig. 1A) . A portion of the latter appeared as well-circumscribed spheres of varying diameters (see below). Counterstaining with cresyl violet verified that the DAB reaction product was localized to cortical cells with the morphology of neurons, particularly, but not exclusively, the larger pyramidal cells (Fig. 1B) . Also, unlike anti-A4 antibody reactivity, blood vessels of normal control brains that were not thioflavin positive were readily immunostained by P2 (Fig. 1C) . Four control brains exhibited similar staining patterns.
Immunostaining of five AD cortices with P2 revealed striking similarities to the control cases since both neuronal and other elements were visualized (compare Fig. 1 A and D) . Similar observations were made on neurons of hippocampus and amygdala, which also exhibited a homogeneous distribution of the antigen over cell bodies and large dendrites (Fig.  1D Insets) . Preimmune serum subjected to the affinitypurification procedure was without appreciable immunoreactivity, as indicated by the matched tissue sections of Fig. 1 E and F. Preincubation of P2 with the immunogen (20 jig/ml) eliminated the characteristic discrete staining of both cellular and noncellular elements in matched sections. Preincubation with A4 peptide (20 ,g/ml) had no effect on P2 immunostaining.
In a previous report, we noticed discrete lamination of A4-positive deposits in the AD cortex (10) . While the distribution of P2 was not uniformly related to cortical lamellae, similar to previous observations, there was a noticeable tendency of P2 reaction product to be more heavily concentrated in supragranular layers.
P2 Antigen Is Associated with Astrocytes. Certain of the smaller cells detected by P2 appeared nonneuronal. This possibility was verified by an AD cortical section that was doubly stained with anti-GFAP and P2 using an immunofluorescence technique and an immmunoperoxidase method, respectively ( Fig. 2 A and B) . P2 Antigen Is Associated with a Subset of Senile Plaques. To determine whether or not senile plaoues contained the P2 Proc. Natl. Acad. Sci. USA 86 (1989) Proc. Natl. Acad. Sci. USA 86 (1989) antigen, AD cortical sections were immunoprocessed and then counterstained with thioflavin S. Certain of the thioflavin S-positive plaques (e.g., Fig. 2C ) contained heavy deposits of P2 reaction product (Fig. 2D) . The distribution and morphologic appearance of P2 antigen in plaques varied from discrete foci, as shown, to a more diffuse appearance. The relationship between sites of A4 deposition in senile plaques and the distribution of P2 antigen was examined by double-immunostaining experiments using a mixture of anti-A4 mAbs (4E12, 5E2, and 1OH3; ref. 10) and P2 antisera applied to AD cortical sections. Plaques containing the A4 region of the APP precursor (fluorescent label, Fig. 2E ) were identified that also contained the P2 region of the extracytoplasmic domain (DAB label, Fig. 2F ). The same results were obtained with A4 and P2 antibodies when double-immunofluorescence methods were used.
Quantitation of P2 and A4 Antigens in Plaques. The presence of an extracytoplasmic APP domain in senile plaques was explored in more detail by quantitative studies applied to additional AD brains. As shown in Table 1 (Exp. 1), those plaques identified by thoiflavin S staining were uniformly A4 positive, and the vast majority (89.5%) of the thioflavin S-positive plaques also contained the P2 antigen. We then examined the quantitative distribution of P2 and A4 antigens within plaques. Consistent with the previous results, doubleimmunostaining studies revealed that 88% of plaques identified by A4 mAbs were also P2 positive ( P2 Antigen Is Associated with CA. We observed that immunostaining of cortical and hippocampal sections with P2 frequently revealed the appearance of spherical bodies containing reaction product at their periphery and/or within the core (Fig. 3A) . The size (usually 10-12.5 am diameter) and morphologic appearance of these elements, as well as their concentration at subpial and perivascular sites, led to speculation that they represented glycogen-containing CA (16); this was confirmed by PAS staining. The resemblance of P2-positive spheres and PAS-positive CA is indicated by comparison of Fig. 3 A and B. Corroborating evidence was obtained by double-staining reactions in which P2-positive spheres were also PAS positive in AD cortex and hippocampus (Fig. 3C) . However, not all PAS-positive CA were P2 positive (Fig. 3C, arrow) tered, P2-positive CA were also observed in the elderly normal brain. Quantitative evaluation of one AD frontal cortex revealed that the P2 antigen was present in 48% of CA examined; in a second AD brain, 85% of hippocampal CA were P2 positive. By contrast, we did not detect the A4 epitope in CA (Fig. 3D) . However, CA were occasionally observed in close proximity to senile plaques (Fig. 3D,  arrows) .
DISCUSSION
Cellular Distribution of Antigens. APP mRNA is found in nonneural tissues as well as brain (2, 17) . However, the A4 peptide is most easily demonstrated by immunologic techniques in extracellular amyloid deposits and affected blood vessels of the AD brain (8) (9) (10) (11) (16, 19) . They have been associated with both neurons (20) (21) (22) and astrocytes (23) . A distinct difference between A4 and P2 antigens was the presence of the latter in CA. Perhaps germane to the present investigations was the observation that, in AD, CA were found within synaptic processes in Alzheimer striatum and caused distortion of synaptic vesicles (24) . It has been known for some time that CA contain a glycogen-like substance (25) and recent studies identified a glycosaminoglycan as a major constituent (26) . It was recently determined that proteoglycan secreted from PC12 cells shares similarities with the ECD of APP (27 of ECD antigen with a number of AD senile plaques. Thus, the possibility exists that more than one processing mechanism is involved in the metabolism of different APP subdomains and that at least one mechanism is unique to the AD brain and involves both A4 as well as non-A4 sites.
